Newsfeed : CDC Switches Direction of Botswana PrEP Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » December 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 21, 2009

CDC Switches Direction of Botswana PrEP Trial

A study already underway in Botswana regarding the usefulness of pre-exposure prophylaxis (PrEP) is being adjusted to account for the dropping HIV rates in that country, Reuters reports.  

PrEP is being studied around the world to determine whether low, daily doses of HIV medications can be used to safeguard HIV-negative people from contracting the virus. The Botswana trials involved Gilead Science’s Truvada (emtricitabine and tenofovir), according to the Centers for Disease Control and Prevention (CDC).  

“We are not giving up on the trial—we are going to complete the trial. We just will not get all of the answers we set out to get,” Terry Butler, the CDC’s director of strategic communications, told Reuters. “The trial protocol and timeline will be revised to focus instead on the other remaining study questions—primarily behavioral and clinical safety and adherence.”  

According to the article, the study—called TDF2—must change directions to account for dropping HIV infection rates in Botswana, where close to a quarter of adults are already living with the virus. Additionally, researchers are having difficulty keeping people enrolled in the trial.  

“The drops in incidence that we are seeing in Botswana and elsewhere are welcome news, requiring new and innovative ways of designing, running and funding trials and of working with communities,” said Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention.

Search: Botswana, pre-exposure prophylaxsis, PrEP


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.